www.cancernetwork.com Open in urlscan Pro
76.76.21.241  Public Scan

Form analysis
2 forms found in the DOM

<form style="padding:6px;width:100%" class="form-inline"><input type="text" style="width:20%;flex-grow:1" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none;width:20%;margin-left:2%"
    type="button" class="btn btn-primary">Search</button></form>

<form style="padding:6px" class="form-inline"><input type="text" style="width:50%;flex-grow:1" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none;width:20%;margin-left:2%" type="button"
    class="btn btn-primary">Search</button></form>

Text Content

CONTINUE TO SITE

OR WAIT null SECS


Search
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer
UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic
OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical
PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast
CancerReal-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC
with Uncommon EGFR Mutations
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer
UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic
OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical
PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast
CancerReal-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC
with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal
CancerGastrointestinal CancerGenitourinary CancerGynecologic
CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
Acute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal
CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung
CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeAwareness MonthBetween the LinesClinical
ConsultExpert InterviewsFace OffMedical World NewsMorning
RoundsOncViewPodcastsReadout 360Year in Review
2 Minute DrillAround the PracticeAwareness MonthBetween the LinesClinical
ConsultExpert InterviewsFace OffMedical World NewsMorning
RoundsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
All JournalsFor AuthorsTumor Board
Events
Frontline Forum
Frontline Forum
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's
AssistantsPartnersSponsored
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's
AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription
eNewsletterPrint Subscription
Search



 * About
 * Advertise
 * CureToday.com
 * OncLive.com
 * OncNursingNews.com
 * TargetedOnc.com
 * Contact
 * Terms and Conditions
 * Privacy
 * Do Not Sell My Personal Information

 * 
 * 

© 2022 MJH Life Sciences and Cancer Network. All rights reserved.


Spotlight
 * 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
 * CancerNetwork® Inaugural Face-Off
 * Contemporary Concepts in Hematologic Oncology
 * Insights from Experts at Mayo Clinic on Translating Evidence to Clinical
   Practice
 * Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
 * Real-World Evidence in NSCLC Guides Clinical Decisions
 * Targeting NSCLC with Uncommon EGFR Mutations

ClinicalSee All >
 * Acute Myeloid Leukemia
 * Brain Cancer
 * Breast Cancer
 * Colorectal Cancer
 * Gastrointestinal Cancer
 * Genitourinary Cancer
 * Gynecologic Cancer
 * Hematology
 * Leukemia
 * Lung Cancer
 * Lymphoma
 * Pediatric Cancers
 * Skin Cancer


 * About
 * Advertise
 * CureToday.com
 * OncLive.com
 * OncNursingNews.com
 * TargetedOnc.com
 * Contact
 * Terms and Conditions
 * Privacy
 * Do Not Sell My Personal Information
 * 

 * 

© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.


ANTITUMOR ACTIVITY NOTED WITH PEMBROLIZUMAB PLUS LENVATINIB IN FRONTLINE
NON–CLEAR CELL RCC

September 13, 2022
Jason M. Broderick




Conference | European Society for Medical Oncology Congress (ESMO)

Findings from the phase 2 KEYNOTE-B61 trial demonstrated promising efficacy with
a combination of pembrolizumab and lenvatinib in the frontline treatment of
non–clear cell renal cell carcinoma.



According to preliminary findings from the phase 2 KEYNOTE-B61 trial presented
at the 2022 European Society for Medical Oncology Congress (ESMO), the
combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) showed
encouraging antitumor activity as frontline treatment for patients with
non–clear cell renal cell carcinoma (nccRCC).



At a median follow-up of 8.2 months (range, 5.5-10.5), the confirmed objective
response rate (ORR) was 47.6% (95% CI, 36.4-58.9), comprising 3 complete
responses (3.7%) and 36 partial responses (43.9%). The disease control rate
(DCR), which also includes stable disease, was 79.3% (95% CI, 68.9-87.4).
Progressive disease occurred in 11% of patients.



The median time to response was 2.8 months (range, 2.6-5.7) and the median
duration of response was not yet reached (range, 1.4+ to 7.2+ months). The
6-month overall survival and progression-free survival rates were 87.8% (95% CI,
78.5-93.2) and 72.3% (95% CI, 60.7-81.0), respectively



“Given the encouraging ORR and DCR, lenvatinib plus pembrolizumab may represent
a potential frontline treatment option for nccRCC,” said lead investigator
Laurence Albiges, MD, PhD, Institut Gustave Roussy, Villejuif, France.





Patients enrolled in the single-arm KEYNOTE-B61 trial (NCT04704219) have
histologically confirmed nccRCC (per investigator) with locally advanced or
metastatic disease and have not received any prior systemic therapy. Overall,
there were 147 patients treated in the trial, and treatment remains ongoing for
123 patients, including all patients who have achieved a confirmed response.



Efficacy was evaluated in the 82 patients who had enrolled on the trial at least
6 months prior to the data cutoff date of January 31, 2022. The RCC histology
for these patients was as follows: papillary (n = 51), chromophobe (n = 15),
unclassified (n = 7), translocation (n = 5), and “other” (n = 4).



In the 82-patient efficacy population, the median age was 64 years, (range,
24-87) and 70.7% of patients were male. The IMDC risk categories were favorable
for 39% of patients and intermediate/poor for 61% of patients. Twelve percent of
patients had sarcomatoid features. About two-thirds of patients had positive
PD-L1 status as determined by a combined positive score of 1 or greater.
Regarding metastases, 17.1% of patients had liver metastases and 29.3% had bone
metastases.



Pembrolizumab was administered intravenously at 400 mg every 6 weeks for a
maximum of 18 cycles (about 2 years). Lenvatinib was administered orally at 20
mg daily. The primary end point was ORR.



In addition to assessing the study population as a whole, the investigators also
determined ORR and DCR across the various histologic subgroups. The ORR and DCR
were 52.9% and 78.4% in the papillary group; 13.3% and 73.3% in the chromophobe
group; 71.4% and 100.0% in the unclassified group; 60.0% and 80% in the
translocation group; and 50% and 75% in the “other” group.



Responses were observed regardless of IMDC risk status, with an ORR of 56.3% in
the favorable risk group and 42% in the intermediate/poor risk group.



PD-L1–positive status enriched patients response with an ORR of 54.5% in these
patients vs 27.3% in PD-L1–negative patients.



The safety population included all 147 treated patients. Albiges said there were
no new safety signals with the pembrolizumab/lenvatinib regimen. Overall, 86.4%
of patients experienced a treatment-related adverse event (TRAE) of any grade.
The most common TRAEs across all grades were hypertension (48.3%), diarrhea
(25.2%), and hypothyroidism (25.2%). Grade 3/4 TRAEs were experienced by 34.7%
of patients and there were no patient deaths related to TRAEs.



Albiges said the results of the study are particularly encouraging given the
high unmet need in nccRCC, with response rates to single-agent tyrosine kinase
inhibitor therapy being “somewhere between 5% and 25% and a progression-free
survival of usually less than 6 months.”



Regarding next steps for this study, she said, “Data from all patients will be
presented when additional follow-up are available.”




REFERENCE



Albiges L, Gurney HP, Atduev V, et al. Phase II KEYNOTE-B61 study of
pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for
non-clear cell renal cell carcinoma (nccRCC). Ann Oncol. 2022;33(suppl 7):14480.
doi:10.1016/annonc/annonc1072






Related Content:

European Society for Medical Oncology Congress (ESMO)Kidney Cancer
Stacey A. Cohen, MD, Discusses the Relevance of ctDNA as a Prognostic Marker for
Resected Stage I-III CRC
Neoadjuvant Pegylated Lipsomal Doxorubicin/Cyclophosphamide Plus
Trastuzumab/Pertuzumab Yields Promising Efficacy in HER2+ Breast Cancer
Favorable Efficacy, Safety of Lenvatinib Plus Pembrolizumab Reported in
Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma
Related Article >>>

--------------------------------------------------------------------------------


x






×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar
technologies on this site and use personal data (e.g., your IP address). If you
consent, the cookies, device identifiers, or other information can be stored or
accessed on your device for the purposes described below. You can click "Allow
All" or "Decline All" or click Settings above to customize your consent.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalized content profile; ●
Select personalised content; ● Personalized ads, ad measurement and audience
insights; ● Product development. For some of the purposes above, our advertising
partners: ● Use precise geolocation data. Some of our partners rely on their
legitimate business interests to process personal data. View our advertising
partners if you wish to provide or deny consent for specific partners, review
the purposes each partner believes they have a legitimate interest for, and
object to such processing.
If you select Decline All, you will still be able to view content on this site
and you will still receive advertising, but the advertising will not be tailored
for you. You may change your setting whenever you see the Manage consent
preferences on this site.
Decline All
Allow All
Manage consent preferences